Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Modafinil Tablets 200 mg Clear all

Conditions: Postural Tachycardia Syndrome
Interventions: Placebo, Modafinil, Propranolol; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Delirium, Respiratory Failure
Interventions: Modafinil, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 46
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more

Conditions: Chronic Shift Work Sleep Disorder
Interventions: PROVIGIL 200 mg, Armodafinil 250 mg, Armodafinil 200 mg, Armodafinil 150 mg, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 20
States / cities: Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 16 more

Conditions: Excessive Sleepiness
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Burlingame, California • San Diego, California • Stanford, California + 5 more

Conditions: Depression
Interventions: Armodafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 867 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 50 more

Conditions: Healthy
Interventions: Modafinil Tablets 200 mg, Provigil® Tablets 200 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Schizophrenia
Interventions: armodafinil, placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 12
States / cities: Garden Grove, California • National City, California • Paramount, California + 9 more

Conditions: Methamphetamine Dependence
Interventions: Modafinil, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: San Diego, California • Tarzana, California • Torrance, California + 5 more

Conditions: Schizophrenia
Interventions: armodafinil, placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 39
States / cities: Little Rock, Arkansas • Anaheim, California • Escondido, California + 32 more

Conditions: Long COVID, Long COVID-19, Hypersomnia
Interventions: Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Modafinil Tablets 200 mg, Provigil® Tablets 200 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 40
States / cities: Birmingham, Alabama • Beverly Hills, California • Garden Grove, California + 36 more

Conditions: Sleep Restriction, Impaired Glucose Metabolism
Interventions: modafinil, placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 20 Years to 35 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Interventions: Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo; Drug · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 47
States / cities: Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more

Conditions: Obstructive Sleep Apnea Syndrome
Interventions: Xyrem (X), Zolpidem (Z), Modafinil (M), Placebo (P); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Tachycardia, Chronic Orthostatic Intolerance
Interventions: Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder; Drug · Other · Dietary Supplement + 3 more
Lead sponsor: Satish R. Raj; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cancer, Fatigue, Chemotherapy
Interventions: Modafinil, sugar pill; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cognition
Interventions: Modafinil 200mg, mixed amphetamine salts, Placebo; Drug
Lead sponsor: United States Army Aeromedical Research Laboratory; Federal
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fort Rucker, Alabama

Search by objective public record fields.

Modafinil and Cognitive Function in POTS

Modafinil Versus Placebo for Hypoactive Delirium in the Critically Ill

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL

Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Food Study of Modafinil Tablets 200 mg to Provigil® Tablets 200 mg

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

Fasting Study of Modafinil Tablets 200 mg and Provigil® Tablets 200 mg

A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction

RECOVER-SLEEP: Platform Protocol

Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients

Treatment of Orthostatic Intolerance

Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer

Enhancing Operational Performance in Healthy Rested Soldiers With Pharmacological Stimulants